Clinical Trial Update: Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial of otilimab in patients with severe pulmonary disease related to COVID-19 has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome

Drugs mentioned

• Otilimab (otilimab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Severe Acute Respiratory Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2022-03-09